The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)

Filter results
Date Title Content PDF
2/10/2025 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the third quarter of 2025
29/09/2025 On corporate transactions: mergers, acquisitions and others The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA)
29/09/2025 On corporate transactions: mergers, acquisitions and others ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA)
24/07/2025 On P&L The Company releases the first half 2025 financial results presentation
24/07/2025 On P&L The Company releases the press release related to the first half of 2025 financial results
4/07/2025 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2025
3/07/2025 Other relevant information The Company informs about the dividends payment. 
18/06/2025 Announcement of general shareholders’ meeting The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors.
8/05/2025 On business and financial situation ROVI informs on the award of a grant in its favor to develop the R&D Project IPCEI - ROVI (LAISOLID)
8/05/2025 Announcement of General Shareholders’ Meeting The Company announces the call of its 2025 Ordinary General Shareholders' Meeting

Pages